---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-007720"
form_type: "8-K"
ticker: "RARE"
cik: "0001515673"
company_name: "Ultragenyx Pharmaceutical Inc."
filed_at: "2023-03-14T23:59:59+00:00"
generated_at: "2026-06-18T03:11:30.341666+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Ultragenyx CMO Bedrosian transitions to advisor; Crombez named new CMO

## Summary
- Camille Bedrosian transitions to Strategic Development Advisor effective May 1, 2023.
- Eric Crombez promoted to EVP, Chief Medical Officer, effective May 1, 2023.
- Bedrosian’s new base salary set at $500,000; target bonus 35%; equity award of 6,900 RSUs and 9,200 options.
- Severance benefits under amended Offer Letter based on current $600,000 salary and 50% target bonus if termination before May 2024.
- Transition is planned, not a sudden departure.

## SEC filing metadata
- accession: 0000950170-23-007720
- form_type: 8-K
- ticker: RARE
- cik: 0001515673
- company_name: Ultragenyx Pharmaceutical Inc.
- filed_at: 2023-03-14T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1515673/000095017023007720/0000950170-23-007720-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1515673/000095017023007720/rare-20230314.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-007720
- JSON: https://secwatch.observer/filing/0000950170-23-007720.json
- Plain text: https://secwatch.observer/filing/0000950170-23-007720.txt

## Key facts
- Executive change
  Eric Crombez was appointed as Executive Vice President, Chief Medical Officer at Ultragenyx Pharmaceutical Inc..
  - Action: appointed
  - Role: Executive Vice President, Chief Medical Officer
  source text: Eric Crombez, M.D., the Company’s current Chief Medical Officer for Gene Therapy and Inborn Errors of Metabolism, will assume the role of Executive Vice President, Chief Medical Officer, effective as of the Effective Date.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1515673/000095017023007720/0000950170-23-007720-index.htm
- Executive change
  Camille L. Bedrosian changed role as Strategic Development Advisor at Ultragenyx Pharmaceutical Inc..
  - Action: transitioning
  - Role: Strategic Development Advisor
  source text: On March 14, 2023, Ultragenyx Pharmaceutical Inc. (the “ Company ”) announced that Camille L. Bedrosian, M.D., the Company’s Executive Vice President and Chief Medical Officer, will be transitioning to a new role as Strategic Development Advisor to the Company, effective May 1, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1515673/000095017023007720/0000950170-23-007720-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.